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Tuberculosis (TB) is second only to HIV in the number of deaths caused by 
infection worldwide, with 9 million new cases and 1.5 million deaths reported 
in 2013 [1]. The Bacille Calmette-Guérin (BCG) vaccine is an approved 
vaccination against TB, although its protection is limited to severe childhood 
disease with no impact on adult pulmonary infection, which drives the spread 
of the global epidemic [2, 3]. The development of an effective vaccine against 
TB would be a major step in meeting the Stop TB Partnership’s goal of 
eliminating TB as a public health concern by 2050 (reviewed in [4]). Here we 
explore a recurrent question in such vaccine design – can antibody-mediated 
immunity (AMI) contribute to protection against TB?  
 
In the late 19th century, the emergence of serum therapy against pathogens 
such as Streptococcus pneumoniae gave rise to hope that a cure for TB 
would soon be found [5]. The ability of serum to agglutinate cultures of the 
tubercle bacillus was demonstrated in the late 1800’s, and trials were 
commenced in an attempt to cure patients with serum taken from horses, 
cows, or pigs that had been inoculated with varying preparations of 
mycobacteria. Despite hints of initial success in resolving symptoms, these 
trials were eventually halted as a result of subsequent equivocal results, 
inadequate controls and variability in the serum preparations. Albert Calmette, 
one of the inventors of BCG vaccination, later summarized the disappointing 
results of serum therapy, “Up to now, therefore, it does not seem that specific 
serotherapy has realized the hopes which it aroused” (reviewed in [5]).  
Subsequently, the lack of correlation between antibody titers and resistance to 
TB, as well as the scientific obstacle of exactly how antibodies would protect 
against an intracellular pathogen, directed the search for a TB vaccine away 
from AMI [2]. The shift in the dichotomy of TB immunity away from AMI 
towards cell-mediated immunity (CMI) crystallized with the rise of the HIV-TB 
syndemic, research on which provided empirical evidence that the 
progressive loss of CD4+ T-cells caused by HIV infection directly relates to 
increasing susceptibility to developing TB [3]. 
 
The current TB vaccine development pipeline reflects this paradigm. The 
underpinning rationale of the vaccination strategy in the past twenty years has 
been to induce a T-cell response against dominant M. tuberculosis (M.tb) 
antigens, in the hope that these T cells could rapidly control primary infection 
and/or prevent progression to active disease [3, 6]. Such an immune 
response may be induced by recombinant forms of BCG, virally vectored 
vaccines or avirulent mycobacteria such as Mycobacterium vaccae or RUTI 
(reviewed in [6]). The MVA85A vaccine is the most advanced candidate of this 
mold, having recently completed a Phase IIb trial in a cohort of 2797 South 
African infants [7].  Although well tolerated and capable of eliciting a recall 
CD4+ T-cell response on stimulation with M.tb antigen, the MVA85A vaccine 
failed to confer any protection against infection or disease [7], nor did it 
prevent disease in HIV-infected patients (Ndiaye et al. Lancet Respir Med in 
press).  The setback of a highly immunogenic T-cell vaccine having no 
efficacy against TB has led to the question of the sufficiency of an isolated 
Th1-type response in protection against M.tb infection, and to a revival in 
interest in the contributions of other arms of immunity, such as non-classically 
restricted T-cells, Th17 cells and antibodies [3, 6].  A vaccine that prevents 
primary infection would have a large impact on reducing the transmission of 
TB, and the induction of protective antibodies has the conceptual advantage 
of being capable of neutralizing or preventing the uptake of the infecting 
inoculum (reviewed in [8]).  The classical strategy of vaccination is to induce 
AMI, even against intracellular pathogens such as Salmonella typhi, with the 
only exceptions in licensed vaccines being for varicella zoster virus and the 
partially effective BCG vaccine [2]. The tetanus toxoid vaccine provides a 
precedent for the induction of “synthetic” immunity; given that antibodies are 
not produced against tetanus toxin during natural infection, antibodies 
generated during infection fail to provide protection, however vaccination with 
the toxoid has been shown to induce antibodies that are highly effective at 
preventing disease [9].  The renewed attention to AMI converges with 
evidence on how antibodies could elicit protection against M.tb, discussed in 
this article, as well as with advances in the ability to investigate the difference 
in efficacy of individual monoclonal antibodies (mAbs) rather than whole 
serum or polyclonal antibody approaches.[2]  
 
Recent research has challenged the long-held notion of a polarization of 
immunity to either a protective cell-mediated response or a non-functional 
antibody response. The granuloma, which is characteristic of organized CMI 
against TB, has been shown to contain B cells – a finding which suggests 
their involvement in orchestrating the containment of infection [10]. The role of 
B cells in the granuloma appears to be immunomodulation through the 
secretion of cytokines such as IL-10, and the production of immunoglobulin to 
engage Fcγ antibody receptors (FcγRs) expressed on mononuclear 
phagocytes (reviewed in [10].  Activation of the FcγR and its downstream 
pathways by antibodies may play a vital role in controlling TB infection. Mice 
with loss of function of the FcγR have been shown to have greater lung 
inflammation and neutrophil infiltration on challenge with TB [11]. Conversely, 
FcγRIIb-/- mice, which lack the inhibitory subtype of the FcγR, have been 
shown to produce more IFN-γ, have less lung pathology and reduced 
mycobacterial burden in the lungs and spleen when challenged with M.tb [11].  
Antibodies bound to the surface of BCG from vaccinated individuals further 
demonstrates this synergy between AMI and CMI by augmenting antigen 
presentation to T cells with a subsequent increase in Th1 cytokine production 
[2]. In light of this, it is interesting to note that the upregulation of the gene for 
the high-affinity antibody receptor, FcγR1A, is a consistently strong finding 
across transcriptomic signatures of active TB patients [12].  The importance of 
this finding may further be inferred from a small cohort of HIV-TB co-infected 
patients in Ethiopia, in whom copy-number deletions of the FcγR3B and 
FcγR2C receptors were associated with greater susceptibility to developing 
TB [13].  Intriguingly, the intracellular antibody receptor TRIM21, capable of 
triggering inflammatory signaling via cytosolic recognition of antibody, has 
been shown to be elevated in TB-infected patients compared with healthy 
controls – a facet of AMI not previously described in the disease [12].  The 
beneficial effector functions of the upregulated antibody receptors during 
human infection would depend on the specificity of the antibodies that are 
capable of engaging them during TB infection. 
 
Current vaccines against bacterial pathogens induce neutralizing antibodies 
against bacillary surface polysaccharides, thus high-affinity antibodies to 
surface constituents of M.tb may be of interest [5, 6].  To this end, efforts to 
map the targets of the antibody response to TB infection have been advanced 
by the utilization of protein microarrays. One such study revealed that 
extracellular proteins secreted by M.tb, not surface antigens, are strongly 
immunodominant in active disease despite representing only 0.5% of the 
entire proteome [15].  . The total immunoproteome includes almost five 
hundred M.tb proteins, with the group of antigens rarely recognized by patient 
sera enriched for membrane-associated proteins [15].  Humans do produce 
antibodies that bind the cell surface of live M.tb, but there appears to be a 
drop in avidity during active infection which may represent antibody class 
switching or the presentation of alternative antigens by M.tb during the course 
of infection [16].  Several immunogenic surface proteins, such as the PE/PPE 
family of proteins, exhibit genetic variability suggestive of antigenic variation – 
an intriguing postulate given that immunodominant T-cell epitopes are 
hypothesized to be evolutionarily hyper-conserved [16,17].  In line with this 
concept, murine mAbs against the surface-exposed heparin-binding 
hemagglutinin (HBHA) protein of M.tb, also a target of the human antibody 
response, have been shown to interfere with bacterial adhesion to 
macrophages and decrease dissemination of bacilli in murine models [2].  
Taken together, these findings lend credence to the possibility that secreted 
antigens could divert the antibody response away from surface proteins 
during active infection because such antibodies may elicit a beneficial host 
immune response.  
 
The mechanisms by which antibodies could function against TB are thought to 
be via modulation of host immunity to more efficiently control infection, or 
through direct anti-mycobacterial properties. In the former case, antibodies 
may opsonize TB, enhance phagolysome maturation and intracellular killing 
or, as discussed, stimulate an amplified cell-mediated response [2].  As an 
example, a human monoclonal IgA against α-crystallin requires the presence 
of both IFN-γ and the FcαR1/ CD89 antibody receptor to elicit protection in 
humanized mice [2].  Immunomodulation may also occur by clearance of pro-
inflammatory secreted proteins to the lymphatic system, resulting in reduced 
localized lung inflammation [2].  The existence of mAbs with direct anti-
mycobacterial effect in humans is speculative but of great interest.  The 
antibody repertoires of healthcare workers exposed to TB who remained 
tuberculin skin-test negative, a theoretically resistant population, revealed a 
preference for a VH3-23, D3-3, JH4 IgA gene recombination which was 
absent in their colleagues with previous active disease or latent TB [19]. One 
plausible explanation for this is that resistant individuals produce IgA in the 
lung mucosa capable of preventing primary infection. The existence of mAbs 
capable of direct disruption of cell wall division or maintenance has been 
demonstrated in C. neoformans, an intracellular pathogen with a waxy 
capsule, where protective mAbs alter lipid metabolism gene expression and 
increase the organism’s susceptibility to antifungal drugs [2].  Whether other 
functions of antibodies that elicit antibody-dependent cytotoxicity and 
complement activation can protect against TB remains to be studied, but it is 
clear from murine models that mAbs against TB can modulate the natural 
history of infection. 
 
Advances in the ability to produce human mAbs against TB may facilitate the 
search for functional antibodies in humans against TB of known specificity. 
New molecular techniques of single B-cell immunoglobulin gene cloning and 
expression have allowed the rapid production of fully human neutralizing 
mAbs to a broad range of pathogens such as dengue, influenza, HIV, malaria 
and streptococcus [20-23].  The pathway of mAb production through to 
epitope-based immunogen development has been validated in the case of 
respiratory syncytial virus (RSV), where the epitopes of commercial 
neutralizing antibodies were mapped and then produced as immunogens that 
elicited protection against RSV in vaccinated macaques. This technique of 
producing human mAbs has also led to the discovery of the novel dengue 
envelope dimer epitope, a target of broadly neutralizing mAbs against live 
virus and derived directly from dengue patients that is encouraging for future 
vaccine design [21,23].  The Bill and Melinda Gates Foundation’s 2014 
revised TB Vaccine Strategy lists the exploration of entirely novel vaccine 
concepts to exploit greater immunological diversity as a key strategic goal, 
and the technology here presents one such an opportunity to harness AMI 
against TB [26].  The original question of whether AMI contributes to immunity 
against TB is once again compelling, and the impetus to deliver a definitive 
answer will surely continue to grow as the search for an effective vaccine 
continues.  
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